These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11581239)

  • 21. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol.
    Jones RN; Fritsche TR; Sader HS; Goldstein BP
    J Chemother; 2005 Dec; 17(6):593-600. PubMed ID: 16433188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vitro activity of daptomycin and other antimicrobial agents against 499 strains of gram-positive cocci causing bloodstream infection].
    Yang QW; Wang H; Sun HL; Xu YC; Xie XL; Chen MJ
    Zhonghua Nei Ke Za Zhi; 2009 Mar; 48(3):220-4. PubMed ID: 19576091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.
    Snydman DR; Jacobus NV; McDermott LA; Lonks JR; Boyce JM
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3447-50. PubMed ID: 11083657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003.
    Sader HS; Fritsche TR; Streit JM; Jones RN
    J Chemother; 2005 Oct; 17(5):477-83. PubMed ID: 16323435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of occurrence and daptomycin susceptibility rates of Gram-positive organisms causing bloodstream infections in cancer patients.
    Sader HS; Fritsche TR; Jones RN
    J Chemother; 2008 Oct; 20(5):570-6. PubMed ID: 19028618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria.
    Piper KE; Steckelberg JM; Patel R
    J Infect Chemother; 2005 Aug; 11(4):207-9. PubMed ID: 16133715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
    Fluit AC; Schmitz FJ; Verhoef J; Milatovic D
    Int J Antimicrob Agents; 2004 Jul; 24(1):59-66. PubMed ID: 15225863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients.
    Rolston KV; Kapadia M; Tarrand J; Coyle E; Prince RA
    Int J Antimicrob Agents; 2013 Jun; 41(6):516-20. PubMed ID: 23481658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
    Schouten MA; Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
    Johnson AP; Mushtaq S; Warner M; Livermore DM
    Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
    Tenover FC; Baker CN
    J Antimicrob Chemother; 1997 May; 39 Suppl A():81-5. PubMed ID: 9511069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A study of in vitro activity of daptomycin against 2679 Gram-positive cocci].
    Zhang FF; Zhao CJ; Wang ZW; Liu WY; Yan W; Peng QS; Jiang S; Guo Y; Liu JB; Chen HB; Li HN; Wang Q; Wang H
    Zhonghua Nei Ke Za Zhi; 2013 Jun; 52(6):474-9. PubMed ID: 24059993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
    Finch RG
    Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
    Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro bactericidal activity of daptomycin against staphylococci.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 2002 Mar; 49(3):467-70. PubMed ID: 11864946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.
    Fluit AC; Schmitz FJ; Verhoef J; Milatovic D
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1007-11. PubMed ID: 14982796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
    Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.